Welcome to this week’s Chutes & Ladders, our roundup of hires, layoffs and retirements across the industry. Please send your store’s good or bad word to Kyle LaHucik, and we’ll feature it here at the end of each week.
Former FDA Commissioner Hahn Joins Flagship Incubated YourBio Health as Interim Marketing Director
Stephen hahn, MD, will be the Interim Chief Medical Officer of YourBio Health.
The former FDA commissioner, who cleared the emergency use of COVID-19 vaccines last year, will be the acting marketing director of the incubated flagship COVID-19 diagnostic and blood collection company. Formerly known as Seventh Sense Biosystems, the company was founded in 2011 and offers post-vaccine antibody tests for COVID-19 that can be used after a stroke from Moderna, another flagship company. Hahn joined the Flagship life sciences incubator earlier this summer. Fierce MedTech
Glympse Bio Selects Gilead Liver Disease Leader As First Chief Medical Officer
Tram, MD, will be Glympse Bio’s first chief medical officer.
After leading the Global Liver Disease Unit for Gilead Sciences, Tran will oversee injectable biosensor technology at Glympse. Tran will help advance the technology throughout clinical development and through the finish line of FDA approval. She specializes in liver and viruses. The main indication of Glympse for biosensors is the detection of non-alcoholic steatohepatitis, fatty liver disease commonly known as NASH. Fierce MedTech
Orchard Therapeutics Takes Novartis Cell and Gene Leader Smart Immune CSO and Promotes CMO
Nicoletta Loggia, Ph.D., is leaving Novartis to become CTO of Orchard.
Loggia headed the global cell and gene therapy unit at Novartis and was a 17-year veteran of Swiss Big Pharma. She is reprising the role of Ran Zheng, who left for Landmark Bio in July.
Loggia is joined by a new Scientific Director Fulvio Mavilio, Ph.D., who held the same position at Smart Immune. He was previously senior vice president of translational science at Audentes Therapeutics. The orchard also promoted Leslie Meltzer, Ph.D., to the Chief Medical Officer. She joined Orchard in 2018 after previously working in medical affairs at Keryx and Biogen. Fierce biotech
> Hiring of decentralized clinical trials software company Medable MaryAnne Rizk, Ph.D., as Director of Strategy. Rizk is the seventh executive to join the company this year and comes from senior positions at Oracle and Medidata Solutions. Fierce biotech
> XNK Therapeutics selected Markus Thor as a business leader. He joined clinical stage immunotherapy biotechnology at North Venture Partners, where he was a Managing Partner. Exit
> Immunitas Therapeutics appointed Seng-Lai “Thomas” Tan, Ph.D., as Scientific Director. Tan joined Bicara Therapeutics’ single-cell genomics biotechnology, where he was also CSO. Exit
> Elizabeth Eagling-Vose will be senior vice president of operations at Enesi Pharma. She joins Vaccitech’s Next Generation Vaccine Biotechnology, where Eagling-Vose was Senior Director and Head of Clinical Operations. Exit
> Seelos Therapeutics promoted Michel Golembiewski to the financial director and Antoine Marciano to the communications manager. Golembiewski joined as Vice President of Finance in January 2019, and Marciano joined as Head of Corporate Communications in January 2019. Exit
> Genezen cell and gene therapy contract development and manufacturing organization named Ray kaczmarek as CEO. Kaczmarek comes from TriLink Biotechnologies, where he was senior vice president of GMP operations. Exit
> Discovery Life Sciences made two executive appointments this week: Shawn levy, Ph.D., to the Scientific Director, and Mike Musgnug as Director of Revenue. Levy joined the specialist in biological samples and biomarkers in 2019, and Musgnug was previously vice president and general manager of the biotechnology unit at Beckman Coulter Life Sciences. Exit and Exit
> Jay Saoud retires from Minerva Neurosciences. Ramana kuchibhatla, Ph.D., will replace him as senior vice president and head of research and development. Kuchibhatla comes from PRA Health Sciences, where he was executive director of global drug development. Exit
> Isabelle Carmona will be the director of human resources for Rocket Pharmaceuticals. Carmona joins Ichnos Sciences’ Rare Childhood Disorders Clinical Stage Biotechnology, where she held the same title. Exit
> Tom stocky becomes vice president of product for machine learning drug discovery and development company insitro. Stocky was previously a technology researcher at Denali Therapeutics and before that, vice president of research and profile at Facebook. Exit
> Protagonist Therapeutics appointed Scott Plevy, MD, is Executive Vice President and Therapeutic Lead of Gastroenterology. Plevy joined biopharma from Senda Biosciences, where he was Scientific Director. Exit
> The new CFO of LocanaBio is Kat Lange. Lange joins JP Morgan’s RNA gene therapy biotechnology, where she was executive director of the healthcare investment banking group. Exit
> Patrick j fowler becomes Senior Vice President of Business Development and Strategy at Vericel, a sports medicine and severe burns company. Fowler is from Sanofi, where he was responsible for the North American strategy for operations and new product development. Exit
> X4 Pharmaceuticals promoted Marie DiBiase, Ph.D., to become its first COO. DiBiase joined Immune System Biotechnology in 2017 after serving as Vice President of Technical Operations at Epirus Biopharmaceuticals. Exit
> Marc Blaustein will be the Chief Operating Officer of Clinical-Stage Microbiome Biotechnology Finch Therapeutics. Blaustein was previously responsible for the business development of Guide Therapeutics, acquired by Beam Therapeutics this year, and prior to that he was CEO of NED Biosystems and Akashi Therapeutics. Exit
> Eloxx Pharmaceuticals selected Ali Hariri, MD, as Chief Medical Officer. He joined Rare Disease Biotechnology from Sanofi, where he was senior global project manager for rare disease clinical development. Exit
> Intrommune Therapeutics appointed Stuart loesch commercial director. Loesch joined clinical stage food allergy biotechnology from ALK, where he was vice president of marketing and business strategy for North America. Exit
> LightDeck Diagnostics has chosen Russ Peloquin as new sales manager and Franck Gill as a product manager. Peloquin joined SQI Diagnostics, where he was vice president of global business operations. Gill joined LightDeck in August 2020 as VP of Manufacturing after serving as VP of Operations at iCarbonX. Exit
> Flamingo Therapeutics named RNA therapy biotechnology Rob MacLeod, Ph.D., its scientific director as part of a collaboration with Ionis. MacLeod is currently Vice President of Oncology Research and Development at Ionis. Exit
> Eric Groen joins Rani Therapeutics as General Counsel. Groen comes to Amgen’s clinical stage biotech, where he spent nearly 20 years, including most recently as Regional General Counsel for Amgen’s business operations in Canada, Latin America, the Middle East and Africa. Exit
> Jonathan I. Lieber is the new CFO of Applied Genetic Technologies. Lieber joins Gene Therapy Biotech from Danforth Advisors, where he was Managing Director. Exit
> Aquarius named Therapeutics Karen tubridy as director of development. Tubridy joined Akebia Therapeutics, where she was Senior Vice President of Global Programs and Director of Development. Exit
> Tim smith will be Senior Vice President and Head of Business Development at PMV Pharmaceuticals. He joined the precision oncology company of Aquarius Therapeutics, where he was commercial director. Exit
> Neoleukin Therapeutics appointed Bill arthur, Ph.D., its vice-president and director of research. Arthur previously spent a decade at Seagen, most recently as Senior Director and Head of Cancer Biology. Exit
> Frank J. Hsu, MD, is Apeexigen’s new chief medical officer. Hsu joins Oncternal Therapeutics’ oncology antibody biopharmacy, where he held the same role. Exit
> Zoran Zdraveski, Ph.D., is now the legal director of the biopharmaceutical company TScan Therapeutics on cell therapies. Zdraveski was previously Director of Legal and Technology Operations at Magenta Therapeutics. Exit
> Biotech Biophytis on age-related diseases at the named clinical stage Rob van maanen, MD, his chief medical officer. He was previously CMO at Dutch biotechnology Khondrion and before that Senior Medical Director at Astellas. Exit